Former Senior Vice President, Chief Financial Officer and Treasurer · Akebia Therapeutics, Inc. (AKBA)

Ellen Snow

A named executive officer of Akebia Therapeutics in every fiscal year CompBrief holds from FY2023 to FY2024. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2024

$1,048,621

Salary $99,641Stock awards $250,824

FY2023: $1,715,814

6th of 6 named executive officers at Akebia Therapeutics by FY2024 total.

6 named officers on file for Akebia Therapeutics, FY2024

Ellen Snow’s pay file — $29

  • 2 fiscal years of pay, line by line
  • 4 equity grants, each cited to its filing
  • AKBA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Akebia Therapeutics’s whole pay program stands against its peers

  • Akebia Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on AKBA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2025 (DEF 14A).

Free

Get Ellen Snow’s full pay file as a PDF — free

More than this page: up to 10 years of Ellen’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Ellen Snow compensation by year

Akebia Therapeutics Summary Compensation Table · all 2 fiscal years held
In US dollars, as Akebia Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023FY2024
Salary$216,346$99,641
Bonus$0$0
Stock awards$617,900$250,824
Option awards$786,596$325,383
Non-equity incentive$85,438$0
Pension and deferred compensation$0$0
All other$9,534$372,773
Total$1,715,814$1,048,621

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Akebia Therapeutics, Inc. DEF 14A filed April 29, 2025, accession 0001517022-25-000023, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Akebia Therapeutics, Inc. filed document, accession 0001517022-25-000023. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2025.

$1.7M
$1.0M
FY23
FY24
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2024 year-end
TypeUnvested unitsValue at year-endExercise price
RSU395,967$752,337—
Option224,000—$1.68
Option385,000—$1.67

Per the Outstanding Equity Awards at Fiscal Year-End table in Akebia Therapeutics, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.

Akebia Therapeutics’s named executive officers, FY2024

as the company reported each
Named executive officerRoleFY2024 total
John ButlerPresident and Chief Executive Officer$4,260,114
Nicholas GrundSenior Vice President, Chief Commercial Officer$1,854,631
Steven BurkeSenior Vice President, Chief Research & Development and Medical Officer$1,811,027
Erik OstrowskiSenior Vice President, Chief Financial Officer, Chief Business Officer and Treasurer$1,215,122
Michel DahanFormer Senior Vice President, Chief Operating Officer$1,212,463
Ellen Snow · this pageFormer Senior Vice President, Chief Financial Officer and Treasurer$1,048,621

The full Akebia Therapeutics compensation record

free company brief

This page is one person within Akebia Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Akebia Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Akebia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Ellen Snow's compensation dossier · One-time report. No refunds.